Navigation Links
Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
Date:11/9/2010

ially successful or will effectively enhance our businesses or their market value, or that the MedPodium product line can be successfully broadened to include additional healthy lifestyle opportunities, or that we can effectively promote commercialization of our products on our own or through third parties; that improvements in the formulation or use of Generx will be commercially practicable, or that Generx could be successfully advanced as a therapeutic in developing markets or that the results of studies in such markets could be used to advance or broaden the commercialization of Generx in the U.S. or other markets; that Nitric Oxide or other technologies we investigate can be used to effectively expand or improve our product portfolio; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that we can develop a DNA-based orthobiologics product portfolio; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our depen
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
2. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
3. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
4. Cardium Regains Listing Compliance With NYSE Amex
5. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
6. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
7. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
8. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
9. Cardium Completes $6.0 Million Registered Direct Offering
10. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
11. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... that American Indians largely were wiped out by diseases ... brought to the New World by European explorers., One ... lived in the Americas shortly before Europeans arrived, and ... diseases., But new research led by anthropological geneticists Anne ... the University of Tubingen in Germany indicates the diagnosis ...
(Date:8/20/2014)... Group finds that the vascular access device market in ... and China (BRIC) was valued ... of the United States market that year. ... as a result of strong economic expansion, improving access to healthcare ... Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... JOSE, Calif. , Aug. 20, 2014 /PRNewswire-iReach/ ... highlights the transformative collaboration between the school,s bioengineering ... As part of the Intel® Software Academic Program, ... computer sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
... , SAN DIEGO, Dec. 11 Ambit ... Texas M. D. Anderson Cancer Center of the first patient in the ... Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid ... selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 ...
... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... of Dr. Alan Warrander to the role of Senior ... Warrander will be responsible for the execution of the ... President and CEO of Oncolytics. "Having reached an agreement ...
Cached Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... NOAA/Virginia Sea Grant has awarded Virginia Tech $119,000 to ... virus in both shucked and unshucked oysters. , The ... High Pressure Processing Laboratory, and Laura Douglas, lab manager, ... schedules. The laboratory is a facility of the Department ...
... a new protein that plays a critical role in enabling ... or stress, as well as in the progressive loss of ... Their findings, they said, suggest new approaches to prevent or ... in the U.S. The team reports its findings in the ...
... lifespan in yeast, worms, and flies keeps blood sugar ... the August Cell Metabolism. The findings suggest therapeutic interventions ... as type 2 diabetes, which frequently arise with age, ... with an excess of the protein Sirt1 in cells ...
Cached Biology News:Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied 2Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy 2Life-extending protein keeps blood sugar in check 2
... Protein Purification Plates are designed for quick ... The 96-well plates feature two 0.25mm holes ... each well. The wells remain liquid-tight during ... during which time the protein diffuses from ...
... the state-of-the-art in permanent mounting media. ... preservation of immunohistochemical organic insoluble substrates ... New Fuchsin, and any other organic ... sections. Clarin can be used for ...
... industry's first siRNA sequence design software in ... these tools consistent with new experimental strategies ... of RNAi. With the introduction of ... tools, OligoEngine is pleased to offer the ...
... been designed and created in order to ... genotyping analysis tool. We incorporated the suggestions ... the software. Their main requirements were ease- ... acquisition cost. GeneMarker can perform analysis ...
Biology Products: